Latham & Watkins LLP represented Purigen in the transaction. Bionano Genomics, Inc. (NASDAQ: BNGO) has entered into a definitive agreement to acquire Purigen Biosystems, Inc., a...
Bionano Genomics’ Acquisition of Purigen Biosystems
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Octagon Therapeutics’ Research Alliance with Novo Nordisk
Latham & Watkins represented Octagon Therapeutics in the transaction. Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a...
Alignment Healthcare’ $250 Million Debt Financing
Latham & Watkins represented Alignment Healthcare in the transaction. Alignment Healthcare, Inc.(Alignment Healthcare) (NASDAQ: ALHC), a leading tech-enabled MedicareAdvantage company, has announced the close of an...
Ardelyx’s $20 Million Agreement with HealthCare Royalty Partners
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Ventus Therapeutics’ $140 Series C Financing
Latham & Watkins represented SoftBank Vision Fund 2 in the transaction. Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and computational tools to identify and develop small molecule...
CooperCompanies’ Acquisition of Cook Medical’s Reproductive Health Business
Latham & Watkins represented CooperCompanies in the transaction. CooperCompanies has announced it has signed a binding letter of intent to acquire Cook Medical’s Reproductive Health business, a manufacturer...
Innocoll Biotherapeutics’ $125 Million Term Loan Facility
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
UPSIDE Foods’ Acquisition of Cultured Decadence
Latham & Watkins represented UPSIDE Foods in transaction. UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, has announced the...
Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...